Recent studies have shown that almost 30–50% of IBD patients do not respond to anti-TNF therapy: as a consequence, the research currently focuses on nutraceutical compounds that could be useful in the treatment of IBD patients [6,7,8]. This evidence concerns the gene TNF and inflammatory bowel disease.